1. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
- Author
-
Jain, P, Aoki, E, Keating, M, Wierda, WG, O’Brien, S, Gonzalez, GN, Ferrajoli, A, Jain, N, Thompson, PA, Jabbour, E, Kanagal-Shamanna, R, Pierce, S, Alousi, A, Hosing, C, Khouri, I, Estrov, Z, Cortes, J, Kantarjian, H, Ravandi, F, and Kadia, TM
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Cancer ,Hematology ,Rare Diseases ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers ,Tumor ,Chromosome Aberrations ,Disease Progression ,Disease-Free Survival ,Humans ,Kaplan-Meier Estimate ,Karyotype ,Leukemia ,Prolymphocytic ,T-Cell ,Medical Records ,Multivariate Analysis ,Proportional Hazards Models ,Recurrence ,Remission Induction ,Retrospective Studies ,Risk Factors ,Stem Cell Transplantation ,Texas ,Time Factors ,Treatment Outcome ,T-PLL ,prolymphocytic leukemia ,prolymphocytes ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundT-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL.Patients and methodsWe reviewed the clinico-pathologic records of 119 consecutive patients with T-PLL, who presented to our institution between 1990 and 2016.ResultsOne hundred and nineteen patients with T-PLL were analysed. Complex karyotype and aberrations in chromosome 14 were seen in 65% and 52% patients, respectively. Seventy-five patients (63%) were previously untreated and 43 (37%) were initially treated outside our institution. Sixty-three previously untreated patients (84%) received frontline therapies. Overall, 95 patients (80%) have died. Median overall survival (OS) from diagnosis was 19 months [95% confidence interval (CI) 16-26 months]. Using recursive partitioning (RP), we found that patients with hemoglobin
- Published
- 2017